Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 7/20 | 0.46 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918776 | 0.86 | GSK3B (0.49) | JAK3JAK2GSK3BKDM4EMAPT | |
| SCHEMBL2934348 | 0.85 | GSK3B (0.49) | JAK3JAK2CCR6GSK3BDPP4 | |
| Hydrochloric Acid SCHEMBL4281659 | 0.84 | GSK3B (0.48) | JAK3JAK2CCR6GSK3BDPP4 | |
| SCHEMBL2248844 | 0.82 | JAK3 (0.48) | JAK3JAK2CCR6DPP4 | |
| SCHEMBL12680860 | 0.80 | CCR6 (0.43) | JAK3JAK2CCR6GSK3BDPP4 | |
| SCHEMBL1919395 | 0.80 | GSK3B (0.48) | GSK3BKDM4EMAPTTDP1CNR1 | |
| SCHEMBL10270187 | 0.80 | CCR6 (0.43) | JAK3JAK2CCR6GSK3BDPP4 | |
| SCHEMBL2935250 | 0.79 | JAK3 (0.42) | JAK3JAK2CCR6GSK3BDPP4 | |
| SCHEMBL8143524 | 0.78 | GSK3B (0.53) | JAK3JAK2CCR6GSK3BCNR2 | |
| SCHEMBL4287388 | 0.76 | GSK3B (0.51) | JAK3JAK2GSK3BKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| EP-2326639-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | GSK3B, GSK3A, GSKIP | JAK3 96/4885JAK2 11/4885CCR6 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.